Abstract
Pathogenic microorganisms can be suppressed by cell wall destruction. Biosynthesis of peptidoglycans forming bacterial cell wall is interrupted by glycopeptides which inhibit polymerization of a disaccharide formed byN-acetylglucosamine andN-acetylmuramic acid, β-lactams and their derivatives inhibit peptidoglycan cross-linking. Antibiotics inhibiting protein synthesis bind to different sites on the rRNA and interfere with the formation of the polypeptide chain. Tumor cells resistant to chemotherapeutic drugs overproduce proteins transporting the drugs out of cells; these proteins eliminate substances which inhibit transcription of transport proteins. Some antitumor drugs (anthracyclines, fluoroquinolones, acridinesetc.) act at topoisomerases which irreversibly bind to DNA and inhibit DNA synthesis. Immunosuppressants affect various components of the immune system such as T-helper, T-effector cell function, antigen presentation and B-cell function. Antiparasitics — avermectins — bind to a receptor of this Gab-gated chlorine channel in the nerve fiber of nematodes and anthropodes, increasing the permeability of the membrane for chloride ions; the increased transport of chloride ions into the cell causes the death of the parasite. Ionophores dissolve in phospholipid bilayers and enormously increase their ionic permeability. Respiration inhibitors block the transport of electrons at several places of the respiratory chain. Rifamycin binds to the β subunit of bacterial RNA polymerase, thereby blocking mRNA synthesis. Antiviral compounds inhibit the transcription of DNA by several mechanisms or by inhibition of viral entry into host cells.
Article PDF
Similar content being viewed by others
Abbreviations
- Dap:
-
meso-2,6-diaminopimelic acid
- Gab:
-
4-aminobutyric acid (Abu)
- GleNAc:
-
N-acetylglucosamine
- MDR:
-
multidrug resistance
- MRP(1):
-
MDR protein (1)
- MurNAc:
-
N-acetylmuramic acid
References
Aeschimann J.R., Dresswr L.D., Kaatz G.W., Rybak M.J.: Effects of NorA inhibitors onin vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains ofStaphylococcus aureus.Antimicrob.Agents Chemother. 43, 335–340 (1999).
Belova L., Tenson T., Xiong L., Mcnichols P.M., Mankin A.S.: A novel site of antibiotic action in the ribosome interaction of evernimicin with the large ribosomal subunit.Proc.Nat.Acad.Sci.USA 98, 3726–3731 (2001).
Bookchin R.M., Etzion Z., Sorette M., Mohandas N., Skepper J.N., Lew V.L.: Identification and characterization of a newly recognized population of high-Na+, low-K+, low-density sickle and normal red cells.Proc.Nat.Acad.Sci.USA 97, 8045–8050 (2000).
Brown M.J.: Mechanism and specificity of action of ribovirin.Antimicrob.Agents Chemother. 15, 747–753 (1979).
Burg R.W., Miller B.M., Baker E.E., Birnbaum J., Currier S.A., Hartman R., Yu-Ling K., Monaglan R.L., Olson G., Putter I., Tunac J.B., Wellick H., Stampley E.O., Oiwa R., Omura S.: Avermectins, new family of potent anthelmintie agents: production organism and fermentation.Antimicrob.Agents Chemother. 15, 361–367 (1979).
Chiao J.S., Yia T.H., Mei B.G., Jin Z.K., Gu W.L.: Rifamycin SV and related ansamycins. pp. 477–478 in L.C. Vining, C. Stuttard (Eds):Genetics and Biochemistry of Antibiotic Production. Butterword-Heinemann, Boston 1995.
Chopra I., Roberts M.: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.Microbiol.Mol.Biol.Rev. 65, 232–260 (2001).
Čikošová M., Blazsek M., Kubiš M., Gajdošíková J., Borošová G.: Biotechnological preparation of the elaiophylin.Folia Microbiol. 49, 731–736 (2004).
Dey S., Ramachandra M., Pastan I., Gattesman M.M., Ambudkar S.V.: Evidence for two nonidentical drug-interaction sites in the humanP-glycoprotein.Proc.Nat.Acad.Sci.USA 94, 10594–10599 (1997).
Ehrlich J., Cofey G.L., Fischer M.W., Hillegas A.B., Kohbeger D.I., Machamer H.E., Rightsel H.E., Roegner F.R.: 6-Diazo-5-oxo-l-norleucine, a new tumor inhibitory substance.Antibiot.Chemother. 6, 487–496 (1956).
Farutani M., Iida T., Yamano S., Kamino K., Maruyama T.: Biochemical and genetic characterization of an FK506-sensitive peptidyl-prolylcis—trans isomerase from a thermophilic archeon.Methanococcus thermolithotropicus. J.Bacteriol. 180, 388–394 (1998).
Feng Z., Barletta R.G.: Roles ofMycobacterium smegmatis d-alanine:d-alanine ligase andd-alanine racemase in mechanisms of action of and resistance to the peptidoglycan inhibitord-cycloserin.Antimicrob.Agents Chemother. 47, 283–291 (2003).
Fukuzava M., Shearer G.M.: Effect of cyclosporin A on T cell immunity. I. Dose-dependent suppression of different murine T-helper cell pathways.Eur.J.Immunol. 19, 49–56 (1989).
Ganoza M.C., Kiel M.C.: A ribosomal ATPase is a target for hygromycin B inhibition onEschericia coli ribosomes.Antimicrob. Agents Chemother. 45, 2813–2819 (2001).
Hancock R.E.W., Chaple D.S.: Peptide antibiotics.Antimicrob.Agents Chemother. 43, 1317–1323 (1999).
Heep M., Beck D., Bayerdoerffer E., Lehn N.: Rifamin and rifabutin resistance mechanism inHelicobacter pylori.Autimicrob. Agens Chemother. 43, 1497–1499 (1999).
Hengstler J.G., Heimerdinger C.K., Schiffer I.B., Gebhard S., Segemüller J., Tanner B., Bolt H.M., Oesch F.: Dietary topoisomerase II-posisons: contribution of soy products to infant leukemia?EXLIJ. 1, 8–14 (2002).
Hillard J.J., Goldschmidt R.M., Licata L., Baum E.Z., Bush K.: Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems.Antimicrob.Agents Chemother. 43, 1693–1699 (1999).
Hopps H.E., Wissemann C.L. Jr., Smadel J.E., Ho R.: Mode of action of chloramphenicol — IV.J.Bacteriol. 218, 561–567 (1956).
Jin S., Gorfajn G., Faircloth G., Scotto W.: Ecteinascidin 743, a transcription-target chemotherapeutic that inhibits MDR1 activation.Proc.Nat.Acad.Sci.USA 97, 6775–6779 (2000).
Kagawa S.-Z., Yamashita Y., Ochiai K., Ando K., Iwasaki T., Tokiguschi T., Nakano H.: Terpentecin and UTC4B, new family of topoisomerase II targeting, antitumor antibiotic produced byStreptomyces: producing organism, fermentation and large scale purification.J.Antibiot. 48, 211–216 (1995).
Khan S.I., Nimrod A.S., Mehropooya M., Nitiss J.L., Walker L.A., Clarl A.M.: Antifungal activity of eupolarine and its action on AND topoisomerases.Antimicrob.Agents Chemother. 46, 1785–1792 (2002).
Kim H., Xia D., Yu C.-A., Xia J.-Z., Kachurin A.M., Zhang L., Yu L., Deisenhofer J.: Inhibitor binding changes domain mobility in the iron—sulfur protein of the mitochondrialbc 1 complex from bovine heart.Proc.Nat.Acad.Sci.USA 95, 8026–8033 (1998).
Kotra L.P., Haddad J., Mobshery S.: Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance.Antimicrob.Agents Chemother. 44, 3249–3256 (2000).
Lee, Sang-Yong, Hang-Sub Kim, Young-Ho Kim, Sang-Bae Han, Hwan-Mook Kim, Soon-Duck Hong, Jung-Joon Lee: Immunosuppressive activity of elaiophylins.J.Microbiol.Bioctechnol. 7, 272–277 (1997a).
Lee, Sang-Yong, Sang-Chul Ha, Young-Soo Hong, Soon-Duck Hong, Jung-Joon Lee: Production of elaiophylin by the strain MCY-846 in a submerged culture.J.Microbiol.Biotechnol. 7, 278–281 (1997b).
MacNeil D.J.: Avermectins, pp. 421–442 in L.C. Vining, C. Stuttard (Eds):Genetics and Biochemistry of Antibiotic Production. Butterword—Heinemann, Boston 1995.
Murray P.R., Pfaller M.A., Rosenthal K.S.:Medical Microbiology, 5th. ed. ASM Press, Washington (DC) 2005.
Nagata K., Sone N., Tamura T.: Inhibitory activities of lansoprazole against respiration inHelicobacter pylori.Antimicrob.Agents Chemother. 45, 1522–1527 (2001).
Noller H.F.: Ribosomal RNA and translation.Ann.Rev.Biochem. 60, 191–227 (1991).
Ogawa H., Yamashida Y., Katahira R., Chiba S., Iwasaki T., Shizawa T., Nakano H.: UCG9, a new antitumor antibiotic produced byStreptomyces. I. Producing organism, fermentation, isolation and biological activities.J.Antibiot. 51, 261–266 (1998).
Omura S., Sasaki Y., Iwai Y., Takeshima H.: Staurosporin, a potentially important gift from microorganisms.J.Antibiot. 48, 535–545 (1995).
Piddock L.V., Jin Y.F., Griggs J.: Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones byStaphylococcus aureus.J.Antimicrob.Chemother. 47, 261–270 (2001).
Rohrer S., Berger-Baechi B.: FemABX peptidyl transferase: a link between branched-chain cell wall peptide formation and β-lactam resistance in Gram-positive cocci.Antimicrob.Agents Chemother. 47, 837–846 (2003).
Russell R.G., Graveley R., Coxon F., Skjdt H., Del Pozo E., Elford P., Mackenzie A.: Cyclosporine A. Mode of action and effects on bone and joint tissues.Scand.J.Rheumatol. 95 (Suppl.), 9–18 (1992).
Sato N., Yusa K., Naito M., Tsuruo T.: Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrugresistant cells.Biochem.Biophys.Res.Commun. 173, 1252–1257 (1990).
Shim J.-H., Lee H.-K., Chang E.-J., Chae W.-J., Han D.-J., Morio T., Yang J.-J., Bothwell A., Lee S.-K.: Immunosuppressive effects of tautomycetinin vivo andin vitro via T cell-specific apoptosis induction.Proc.Nat.Acad.Sci.USA 99, 10617–10620 (2002).
Suzuki K., Nagao K., Monnai Y., Yagi A., Uyeda M.: Topostatin, a novel inhibitor of topoisomerase I and II produced byThermomonospora alba strain no. 1520.J.Antibiot. 51, 991–998 (1998).
Suzuki K., Yamaizumi M., Tateishi S., Monnai Y., Yueda M.: Topostatin, a novel inhibitor of topoisomerase I and II produced byThermomonspora alba strain no. 1520.J.Antibiot. 51, 991–998 (1998).
Suzuki K., Yamaizumi M., Tateishi S., Monnai Y., Uyeda M.: Topostatin, a novel inhibitor of topoisomerases I and II produced byThermomonspora alba strain no. 1520. III. Inhibitory properties.J.Antibiot. 52, 460–465 (1999).
Uyeda M., Yokomizo K., Miyanoto Y., Habid E.-S.E.: Fattiviracin A1, a novel antiherpetic agent produced byStreptomyces microflavus strain no. 2445. II. Biological properties.J.Amtibiot 41, 1035–1039 (1998).
Vester B., Douthwaite S.: Macrolide resistance conferred by base substitution in 23S rRNA.Antimicrob.Agents Chemother. 45, 1–12 (2001).
Wijnholds J., Mol C.A.A.M., Van Demeter L., Dehaas M., Scheffer G.L., Baas F., Beijnen J.H., Scheper R.J., Hatse S., De Clercq E., Balzarini J., Borst P.: Multidrug-resistance protein 5 is a multispecific anion transporter able to transport nucleotide analogs.Proc.Nat.Acad.Sci.USA 97, 74–76 (2000).
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by theGrant Agency of the Academy of Sciences of the Czech Republic (grant no. S 502 0002).
Rights and permissions
About this article
Cite this article
Běhal, V. Mode of action of microbial bioactive metabolites. Folia Microbiol 51, 359–369 (2006). https://doi.org/10.1007/BF02931577
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02931577